December 2023 in “International Journal of Molecular Sciences” Men with early balding showed higher levels of certain genes linked to hair loss and possibly prostate cancer.
August 2023 in “Frontiers in Oncology” New drugs and therapies targeting specific pathways show promise in treating advanced prostate cancer.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
April 2022 in “Indian Journal of Forensic Medicine & Toxicology” PSA can help diagnose high androgen levels in women.
April 2022 in “Diabetes Therapy” Low testosterone does not prevent prostate cancer in men with type 1 diabetes.
The role of 5α-reductase-3 in prostate cancer is unclear and needs more research.
April 2019 in “The Journal of Urology” Some common medications can lower PSA levels in 45-year-old German men.
March 2019 in “European Urology Supplements” Some common medications like metformin, insulin, and ACE inhibitors can lower PSA levels, while statins don't, and low dose finasteride significantly reduces PSA.
January 2018 in “Figshare” There might be a link between male pattern baldness and a higher risk of prostate cancer and testicular cancer.
August 2017 in “Revista de la Facultad de Ciencias Médicas (Quito)/Revista de la Facultad de Ciencias Médicas” Early-onset male baldness may indicate a higher risk of prostate cancer.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
January 2016 in “International Journal of Medical Research and Health Sciences” Baldness (androgenic alopecia) could be a risk factor for prostate cancer.
March 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Prostate cancer screening doesn't significantly reduce death rates and has risks like overdiagnosis and side effects.
February 2013 in “Americanae (AECID Library)” Finasteride may reduce prostate tumor cell invasion and spread.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.
April 2012 in “The Journal of Urology” Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.
March 2012 in “Dermatology Times E-News” Men with pattern baldness may have a higher risk of prostate issues.
November 2011 in “InTech eBooks” Prostate cancer risk is not linked to blood testosterone levels.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
June 2006 in “American Journal of Epidemiology” Higher BMI is linked to a lower risk of non-aggressive prostate cancer and a higher risk of aggressive prostate cancer.
June 2006 in “American Journal of Epidemiology” Long-term diabetes is linked to lower prostate cancer risk.
April 2023 in “Zenodo (CERN European Organization for Nuclear Research)” Chronic use of 1 mg/day finasteride for hair loss may delay prostate cancer diagnosis by lowering PSA levels.
September 2019 in “Human Andrology” Higher serum androgens contribute to male pattern baldness.
August 2019 in “Journal of The American Academy of Dermatology” No link found between hair loss severity and PSA levels in men.
January 2018 in “프로그램북(구 초록집)” No link between hair loss severity and PSA levels in men.
Hair loss at the top of the head is linked to prostate cancer, but other types of hair loss are not.
1707 citations
,
December 2003 in “The New England Journal of Medicine” Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.